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Abstract

Objective: The role of antidepressants in the treatment of bipolar disorder is controversial
due the risks of affective switching and cycle acceleration. Studies of non-comorbid
populations suggest that the risk of switching can be mitigated with the use of a
concomitant mood stabilizer. The majority of patients with bipolar disorder, however,
will experience a comorbid substance use disorder, and little is known about these
individuals because they are typically excluded from clinical trials. We report on switch
rates among bipolar patients recruited from a substance abuse specialty clinic.

Method: All patients entering treatment who had a history of antidepressant use were
screened for bipolar disorder using the Mood Disorders Questionnaire. Those who
screened positive completed a questionnaire on their psychiatric history, and were
interviewed by telephone to confirm their diagnosis using DSM-IV criteria, and to
document response to treatment. Third party informants were also interviewed.

Results: Eighty-seven individuals were enrolled between February 2007 and February
2008, and bipolar disorder was confirmed in 41. The total lifetime switch rate was 76%.
When antidepressants were combined with a mood stabilizer, the switch rate was 56%.
There was no difference between patients with bipolar I and bipolar II disorders. Some
patients had more than one lifetime trial of combination treatment, primarily those who
did not switch on initial exposure. The switch rate per trial was 35%.
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Conclusion: A comorbid substance use disorder may be a relative contraindication to the
use of antidepressants in bipolar disorder. Bipolar I and bipolar II patients reported high
switch rates for both monotherapy and combination therapy.

Key words: Bipolar disorder, substance use disorder, antidepressant-induced mania,
affective switching, bipolar depression
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Introduction

Although antidepressants are commonly prescribed to patients with bipolar disorder,1 the
use of these medications remains controversial.2 While antidepressants are unequivocally
effective in the treatment of major depressive disorder, the evidence for efficacy in
bipolar disorder is mixed.3, 4 Safety concerns include the risk of cycle acceleration in
which periods of euthymic mood are shortened following antidepressant use,5 and
affective “switching,” in which patients with depression develop a manic, hypomanic, or
mixed episode.6

Data on non-comorbid populations suggest that coadministration of an antimanic mood
stabilizer prevents antidepressant-induced switching. A review of 12 randomized trials on
the efficacy and safety of antidepressants in the treatment of bipolar depression found
that patients who took an antidepressant plus a mood stabilizer had a switch rate no
greater than those on placebo plus a mood stabilizer.7 The switch rate for subjects taking
antidepressants was 3.8% compared to 4.7% for those taking placebo. Reliance on mood
stabilizers to prevent affective switching caused by antidepressants is also reflected in
treatment guidelines which place this combination high on the list of options
recommended for the treatment of bipolar depression.8, 9

Risk factors for antidepressant-induced switching include multiple antidepressant trials,10
previous antidepressant-induced manias,11 and comorbid substance use disorders.12, 13
The majority of patients with bipolar disorder experience a substance use disorder at
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some time during their lives, making the latter risk factor clinically important.14
Unfortunately, little empirical data exist to clarify the magnitude of the risk, in part
because substance use disorders are a routine exclusion criteria for patients entering into
clinical trials. Only two published studies have looked at this risk factor. A patient
interview study of 53 patients with bipolar disorder which included 17 patients who had a
history of a comorbid substance use disorder found that comorbid patients were more
likely to have experienced an antidepressant-induced mania.12 In this study switch rates
on antidepressant monotherapy versus coadministration with a mood stabilizer were not
separately reported for the comorbid group. The overall switch rate was 39.6%, and
within this group, those with a history of a substance use disorder were approximately
seven times more likely to have experienced a switch event compared to those without
such a history.

A chart review study of 98 patients treated in a bipolar specialty clinic, 55 of whom had a
comorbid substance use disorder, looked specifically at the use of the combination of an
antidepressant and a mood stabilizer.13 In the unadjusted analysis antidepressant induced
mania occurred in 20.7% of trials given to patients with a history of a substance use
disorder, and 21.4% of trials given to those without a history of a substance use disorder.
A multivariable regression model that controlled for clinical differences between the two
groups found a five-fold increased odds of antidepressant-induced mania in the substance
using group.
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In this report we add to the limited research on this topic by evaluating history of
antidepressant-induced switches in a group of patients recruited from a specialty clinic
for substance use disorders. We report on rates of switches both with and without
concomitant mood stabilizers. Patients with both bipolar I and bipolar II disorder were
included in the analysis in order to shed light on the question of whether antidepressant
treatment is safer in the latter group compared to patients with bipolar I disorder.

Method

Study participants were recruited from the Kolmac Clinic, a private outpatient treatment
center for substance use disorders located in metropolitan Washington, DC. All patients
entering treatment at the Kolmac Clinic were screened for psychiatric disorders during
the initial evaluation. Patients who screened positive for probable bipolar disorder on the
Mood Disorders Questionnaire (MDQ), using the standard cut off score of seven,15 and
had a history of taking an antidepressant were offered participation in the study.

Patients who agreed to the informed consent were given a questionnaire in which they
entered the following information: the names of all drugs of abuse used and the date of
first use, history of diagnosis with depression and bipolar disorder, and the history of and
clinical response to antidepressants and mood stabilizers. Subjects were also requested to
provide contact information for a third party who knew them well, and to whom the
subject was willing to have us speak about the subject’s mood disorder. The purpose of
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the third party contact was to attempt to identify manic, hypomanic, or mixed episodes
that were not reported by the subjects.

Follow up interviews were done by telephone after the completion of the questionnaire.
The purpose of the interview was to confirm a diagnosis of bipolar disorder, verify the
accuracy of the information reported on the questionnaire, and obtain detailed
information on the subject’s history of treatment with antidepressants and mood
stabilizers. All interviews were done by psychiatrists, and diagnoses were defined using
DSM-IV criteria.

Establishing a diagnosis of bipolar disorder independent of symptoms of a substance use
disorder can be challenging, and requires a careful evaluation of the nature and time
course of the symptoms.16 The probability of the presence of bipolar disorder was
evaluated based on the following: a clear history of a manic, hypomanic, or mixed
episode prior to the onset of substance use; symptoms of abnormal mood that occurred
during periods of abstinence from drug use; symptoms of abnormal mood that occurred
episodically, clustered together, and cycled independently of the substance use;
symptoms of abnormal mood that were qualitatively different from the usual symptoms
of intoxication or withdrawal experienced by the patient; and a family history of bipolar
disorder.17

In order for a switch to be coded as antidepressant-induced, it had to occur within 8
weeks of the initiation of antidepressant treatment. Switches that occurred on the
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combination of an antimanic mood stabilizer and an antidepressant required that the
patient had been taking one or more mood stabilizers at the time of antidepressant
initiation.

An antimanic mood stabilizer was defined as a medication that is approved for the
treatment of acute mania by the Food and Drug Administration (FDA), and included
aripiprazole, carbamazepine, clozapine, divalproex/valproate, lithium, olanzapine,
quetiapine, risperidone, and ziprasidone. Gabapentin, oxcarbazapine, topiramate, and
other medications that have been reported to have mood stabilizing properties were not
classified as mood stabilizers for the purposes of this study. Although lamotrigine is
approved for the treatment of bipolar disorder, it was not included in the list of eligible
mood stabilizers. Some studies have found it to be effective for the treatment of acute
mania,18, 19 however, in general there is a consensus that it lacks a robust antimanic
effect20 and it does not have a FDA approval for this indication.

Third party interviews were conducted following the subject interviews. In order to
minimize loss of privacy, third parties were only told that the subjects were part of a
mood disorder study, and substance abuse was not inquired about, or brought up during
the interview. Third parties were asked about the presence of symptoms of elevated
mood, and were specifically asked to focus on times when antidepressants had been
started.
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The study was approved by the George Washington University Institutional Review
Board.

Results

Between February 23, 2007 and February 17, 2008, 87 patients were enrolled who met
the inclusion criteria, and gave informed consent to participate in the study. All of these
subjects completed a questionnaire. Two subjects could not be reached for a follow up
telephone interview. Of the remaining 85 subjects who participated in a telephone
interview a diagnosis of bipolar I or II disorder was confirmed in 41. The average MDQ
score of these subjects was 11.1 (SD=2.0), compared to 10.1 (SD=2.2) for the 44 subjects
who were not found to have a diagnosis of bipolar disorder.

Table 1 shows the demographic and clinical characteristics of the bipolar patients. As per
the inclusion criteria, all of them had taken an antidepressant, and 61% had been
prescribed a medication approved for the treatment of bipolar disorder. Twenty-three
patients had been prescribed an antidepressant medication while on an antimanic mood
stabilizer. Table 2 lists the drugs of abuse reported by patients. The prescription drug use
frequencies do not include therapeutic use.

Switch rates following antidepressant exposure are shown in Table 3. Overall, switch
rates were high. Most patients had experienced an antidepressant-induced mania. Of

12

those who had ever taken a combination of an antidepressant and antimanic mood
stabilizer, the switch rate was 56%.

Of the 23 patients in this study who had ever received an antidepressant plus an
antimanic medication, 6 had more than one trial such that there were a total of 37
combination trials. Four of the 6 patients who had multiple trials never experienced a
switch, and accounted for 7 of the 13 additional trials. One patient had three trials, and
switched all three times, and one patient had five trials, and only switched following the
final one. In total, there were 37 trials of an antidepressant plus a mood stabilizer and 13
switches giving a switch rate of 35%.

The risk of switching on the combination of an antidepressant and a mood stabilizer was
not significantly correlated with a subject’s age, gender, MDQ score, the MDQ
seriousness item, or the number of substances they had misused. The number of subjects
was too small to meaningfully analyze any association of the risk of switching with
individual substances used or individual medications taken.

Of the 85 subjects interviewed, 34 provided contact information for a third party that
could be successfully reached. In five of these cases the third party identified a manic,
hypomanic, or mixed episode that led to either a change in diagnosis, or a change in the
classification of whether or not the subject switched in response to an antidepressant or to
an antidepressant and mood stabilizer combination.
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Discussion

The percentage of patients who reported switching, that is, converting from a major
depressive episode to a manic, hypomanic, or mixed episode, in response to the
combination of an antidepressant and a mood stabilizer, was substantially higher than has
been reported in studies of non-comorbid patients.7 There are a number of possible
explanations for this finding.

Substances of abuse may have a toxic effect on the brain, thereby worsening the course of
a comorbid mood disorder. Data has shown that compared to patients with non-comorbid
bipolar disorder, those who also have a substance abuse disorder experience more severe
pathology, and less favorable outcomes, including higher rates of mixed states, rapid
cycling, impulsivity, aggression, and destabilization of sleep patterns.22 It is possible that
substance abuse increases a patient’s vulnerability to the mood destabilizing effects of an
antidepressant, or decreases responsiveness to mood stabilizers.

Another possibility is that substance abuse is a marker of a bipolar disorder that is
inherently more unstable. Patients with a more severe form of the illness may be more
likely to self-medicate with substances of abuse, or seek the hedonic effects of substance
use during periods of elevated mood.

Finally, the risks of substance abuse and antidepressant induced mania may both be
expressions of an underlying neuropsychiatric abnormality. Drugs of abuse interact with
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brain systems that are normally involved in the process of incentive, motivation, and
reward.22 Disturbances in drug reward are mediated, in part, by dysregulated neural
integration of dopamine and glutamate signaling in the nucleus accumbens.23 Similar
disturbances have been implicated in other psychiatric disorders, including bipolar
disorder.24, 25 Patients with more severe pathology in these areas may be at greater risk for
both substance abuse and mood instability. Genetic factors may also play a role in these
types of disturbances. For example, Post and colleagues reported that bipolar patients
with more chronic symptoms of abnormal mood were more likely to have a family
history of substance abuse.26

The MDQ had poor specificity in this sample. Only 48% of the patients who screened
positive on the MDQ had a diagnosis of bipolar disorder confirmed by telephone
interview. The average MDQ score of patients diagnosed with bipolar disorder was 11.1,
compared to 10.1 for patients who were not given this diagnosis. This difference was not
statistically significant. The original sample that was used to validate the MDQ recruited
patients from mood disorder specialty clinics, and found a specificity of 0.90.15 A general
population study also found a high specificity of 0.972, however the sensitivity in this
sample was low.27 Symptoms of intoxication can closely mimic symptoms of mania, and
the MDQ does not ask respondents to attempt to identify the etiology of their symptoms,
only to document the presence or absence of them over the course of the respondent’s
entire history. Consequently, it is not surprising that there were more false positives than
true positives in this sample, and the results support the need to screen for comorbid
substance abuse when interpreting a positive MDQ. Only patients with a positive MDQ
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screen were included in this study, therefore the sensitivity could not be calculated in this
sample.

Even for a trained diagnostician, one of the challenges of the cross-sectional,
retrospective nature of this study was making an accurate diagnosis of bipolar disorder in
the context of a co-occurring substance use disorder. Correct diagnoses are most readily
made when a patient can be observed longitudinally, especially during extended periods
of abstinence.28 In order to increase the accuracy of the diagnosis, all interviews were
performed by psychiatrists, and an emphasis was placed on evaluating the time course of
symptoms, whether the apparent symptoms of elevated mood were qualitatively different
from those of substance intoxication, and whether the mood symptoms cycled
independently of substance use patterns.

As noted above, efforts to carefully distinguish symptoms of bipolar disorder from
symptoms of a substance use disorder resulted in more than half of the patients who had a
score of seven or more on the MDQ being classified as not having bipolar disorder.
Because of the substantial risk of misdiagnosis in comorbid patients, a high degree of
confidence in the diagnosis of bipolar disorder was required for a patient to be included
in the analysis. This may have led to a bias toward patients with more classic or more
severe manifestations of bipolar disorder, which may in turn have resulted in the
recruitment of a sample more likely to have experienced an antidepressant-induced
switch.
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Two analyses were performed. The percentage of patients who experienced a switch on
the combination of an antidepressant and mood stabilizer (56%), and the percentage of
antidepressant plus mood stabilizer trials that resulted in a switch (35%). The first
analysis would tend to overestimate the true risk because some of the patients had more
than one trial, but did not switch every time. A clinician would be more interested in the
risk of switching with a specific trial rather than the lifetime risk in the context of
multiple trials.

The second analysis is more comparable to the non-comorbid literature in which the risk
was assessed in the context of a single clinical trial. This analysis, however, in the current
study may underestimate the true risk. Patients who do not switch as a result of past trials
may be more likely to receive future trials. Conversely, patients who do switch would be
less likely to be given an antidepressant in the future. This tendency would mean that the
least vulnerable patients would receive the most trials. In spite of the potential bias
toward underestimation in this type of analysis, the risk was nevertheless nine times
higher than has been reported in non-comorbid samples.7

The lifetime rate of any switch, whether in combination with a mood stabilizer or not was
76%. This rate is substantially higher than found in other studies that did not specifically
focus on substance abusing patients. A similar analysis from the STEP-BD program, in
which self-reported histories of antidepressant-induced switching were evaluated
retrospectively, found a lifetime switch rate of 44%.10 The STEP-BD sample included
some patients with substance abuse histories, however the results were not reported
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separately for these patients. Although some studies have reported comparable switch
rates on or off mood stabilizers, patients in this study had lower rates when being treated
with combined therapy. This difference was seen in patients with both bipolar I and
bipolar II, suggesting that in this population of substance abusers, antidepressant
monotherapy is contraindicated in both diagnostic groups.

This study has a number of limitations. There was no comparison group of patients
without comorbid substance abuse. As a result, the high switch rate seen in this
population may not be solely attributable to the presence substance abuse. There may
have been other characteristics of this population that made them vulnerable to
antidepressants. Another consequence of the absence of a comparison group was that the
assessment was not blinded, and the data may have been affected by measurement bias.
Additionally, the collection of data was dependent upon the memory of patients, and may
have been subject to recall bias.

Despite the significant limitations, in the context of the poverty of literature with regard
to substance use disorders as a risk factor for antidepressant-induced switching, this type
of retrospective data can contribute to generalizable conclusions about the role of
antidepressants in the treatment of comorbid bipolar patients. The highest quality data
would require a randomized, double-blind, placebo-controlled design, however, this type
of study would be difficult given the ethical constraints of double-blind studies.29 In order
to preserve patient safety, those who developed early symptoms of switching would have
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to discontinue study medication, and receive treatment for these symptoms, precluding
the use syndromal manic, hypomanic, or mixed states as an outcome measure.

The appropriate role of antidepressants in the treatment of bipolar disorder remains to be
conclusively established. While the risk of induction of rapid cycling, and other forms of
long-term destabilization is largely unknown with the newer antidepressants, much of the
literature supports the belief that the short-term risk of switching can be adequately
managed with the concomitant use of a mood stabilizer. The data that supports this
treatment strategy is derived primarily from non-comorbid samples, however the high
prevalence of substance use disorders among individuals with bipolar disorder, suggests
that those results may not necessarily generalize to more typical clinical environments.
The results of this study support the use of caution when prescribing antidepressants,
even when given with a mood stabilizer, and a history of substance use disorder may be a
relative contraindication to the use of this treatment strategy.
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Table 1. Clinical and Demographic Information (n=41). Continuous measures shown as
averages with standard deviations in parentheses. Discreet measures are shown as the
number of patients with percentages in parentheses.

Age

39.0 (SD=11.0)

Male

20 (49%)

Female

21 (51%)

Lifetime number of drugs of abuse

4.2 (SD=2.2)

MDQ score

11.1 (SD=2.0)

Bipolar I

18 (44%)

Bipolar II

23 (56%)

Lifetime use of an antidepressant

41 (100%)

Lifetime use of an FDA approved medication for bipolar disorder

25 (61%)

Received an antidepressant while on an antimanic medication

23 (56%)

1

Table 2. Lifetime history of substances abused by bipolar subjects (n=41).

Drug

N (%)

Alcohol

40 (97.6)

Cannabis

36 (87.8)

Cocaine

24 (58.5)

Methylenedioxymethamphetamine (Ecstasy)

17 (41.5)

Lysergic acid diethylamide (LSD)

12 (29.3)

Ketamine

9 (22.0)

Benzodiazepines

7 (17.1)

Methamphetamine

7 (17.1)

Prescription opioids

7 (17.1)

Heroin

6 (14.6)

Phencyclidine (PCP)

4 (9.8)

Prescription stimulants

4 (9.8)

1

Table 3. Lifetime history of experiencing a mood switch from a major depressive episode
to a manic, hypomanic, or mixed episode in response to an antidepressant trial.

Diagnosis

Switch Rate

With or without a concomitant antimanic medication
Bipolar I and II

31 of 41 (76%)

Bipolar I

15 of 18 (83%)

Bipolar II

16 of 23 (70%)

In combination with an antimanic medication
Bipolar I and II

13 of 23 (56%)

Bipolar I

8 of 14 (57%)

Bipolar II

5 of 9 (56%)

